Report date: Thursday, July 30, 2026, after market close
Conference call: 4:30 p.m. ET (investors.dexcom.com)
Dexcom enters Q2 with a better operating backdrop than it had a year ago: the G7 15 Day rollout is gaining scale, manufacturing efficiency has improved, international growth remains healthy, and the CONNECT trial substantially strengthened the case for eventually expanding CGM coverage to people with type 2 diabetes who do not use insulin.
The central question tomorrow is not whether the long-term addressable market is large. It is whether Dexcom can translate that opportunity into consistent low-double-digit U.S. growth while preserving the sharp margin recovery seen in Q1.
A routine consensus beat may not be enough. The shares have risen roughly 31% from their May 14 Investor Day close and trade around 29–30 times the current 2026 EPS consensus. Investors will likely want evidence that G7 15 Day is improving new-patient acquisition, retention and unit economics—not simply shifting existing users from one Dexcom product to another. (barchart.com)
Public estimate aggregators currently cluster around the following:
| Metric | Q2 2026 expectation | Q2 2025 actual | Approx. growth |
|---|---|---|---|
| Revenue | $1.29–$1.30 billion | $1.157 billion | 11%–12% |
| Adjusted EPS | ~$0.61 | $0.48 | ~27% |
| FY2026 revenue consensus | ~$5.22 billion | — | Near guidance midpoint |
| FY2026 EPS consensus | ~$2.57 | — | — |
Estimate providers differ slightly, but $1.29–$1.30 billion and approximately $0.61 per share represent a reasonable consensus range. (benzinga.com)
Dexcom’s existing full-year guidance is:
Assuming Q2 revenue of $1.29 billion, the current annual range would require approximately $2.68–$2.77 billion of second-half revenue. The Street is therefore already near the midpoint of management’s annual range; maintaining guidance would be acceptable, but a stronger stock reaction probably requires either a raise or commentary indicating that the upper half is becoming more likely.
U.S. revenue grew 11% in Q1, versus 26% reported and 17% organic growth internationally. Management said global new-patient starts reached a record, but U.S. starts were only close to a record. Q2 needs to show that domestic momentum is strengthening as G7 15 Day gains awareness and coverage for non-insulin users expands. (investors.dexcom.com)
The most useful disclosures would be:
A total revenue beat driven mainly by favorable currency or international performance would be less compelling than a quarter showing accelerating U.S. adoption.
G7 15 Day is the most important near-term operating lever. Longer wear should reduce sensor changes, improve convenience and lower per-day manufacturing and distribution costs. Management previously expected nearly half of the U.S. base to transition by year-end.
Investors should listen for:
The July 13 authorization of G7 15 Day in Canada is an early step in the international rollout, but the commercial launch timetable and reimbursement positioning will matter more than the regulatory milestone itself. (investors.dexcom.com)
Q1 was exceptionally strong: non-GAAP gross margin reached 63.5%, up from 57.5% a year earlier, while non-GAAP operating margin rose to 22.2% from 13.8%. Management attributed the improvement to manufacturing efficiencies, normalized freight, inventory improvements and the initial benefit of G7 15 Day. (investors.dexcom.com)
The Q2 margin debate has two sides:
Positive
Potential headwinds
A gross margin around or above the upper end of the 63%–64% annual range, accompanied by unchanged cost assumptions, would create room for another margin-guidance increase. Conversely, a return below 63% would raise questions about how repeatable Q1’s improvement was.
A revenue-guidance increase would be positive, but investors should distinguish between:
The strongest outcome would be higher organic expectations accompanied by stable or improving margins. A reported-revenue raise driven primarily by currency would be less meaningful.
On profitability, management already raised operating-margin and EBITDA-margin guidance after Q1. Another increase would signal that the company’s cost structure and G7 15 Day economics are improving faster than originally planned.
The CONNECT randomized trial produced an average 1.6-percentage-point A1C decline from an 8.8% baseline for G7 users, a 0.9-point greater reduction than the control group. Participants also spent five additional hours per day in the target glucose range. Benefits were reported across medication groups, including GLP-1 and SGLT2 users. (investors.dexcom.com)
This materially strengthens Dexcom’s reimbursement case, but it is primarily a 2027-and-beyond catalyst, not a Q2 revenue driver. At Investor Day, Dexcom modeled broad Medicare non-insulin coverage taking effect around mid-2027. Investors should seek an update on:
The key is avoiding excessive near-term expectations. The clinical result improves the probability of coverage, but the timing and eventual adoption curve remain uncertain.
Dexcom began rolling out a redesigned Stelo app in July and plans launches in the U.K., Australia, New Zealand and South Korea beginning later this year and continuing into 2027. The company also acquired Nutrisense to add nutrition education and coaching capabilities. (investors.dexcom.com)
More recently, Dexcom became the first company selected for the FDA’s TEMPO digital-health pilot. Its program combines G7 and Stelo data with nutrition, activity, sleep and stress information to generate personalized insights and evidence around prediabetes and earlier intervention. This is strategically important but unlikely to materially affect Q2 results. (investors.dexcom.com)
Management should clarify Stelo’s:
Dexcom authorized a new $1 billion share-repurchase program in May, with authorization running through June 30, 2027. The company had $2.42 billion of cash, equivalents and marketable securities at the end of Q1. (sec.gov)
Investors should expect an update on repurchase activity. At the current market capitalization, the full authorization is meaningful, but the pace of execution—and whether it offsets stock-based compensation—will determine the EPS benefit.
Abbott reported that Q2 continuous-glucose-monitor sales grew 11% reported and 9.5% on a comparable basis. That suggests the CGM category remains healthy, but growth is no longer uniformly near 20%, making market-share execution increasingly important. Abbott also secured CE Mark for Libre Duo, its glucose-and-ketone sensor, underscoring continuing product competition. (sec.gov)
For Dexcom, a Q2 growth rate above Abbott’s comparable CGM growth would support the share-gain narrative—particularly if it is accompanied by strong U.S. results.
The setup is constructive but execution-sensitive. Dexcom’s clinical evidence, product pipeline and long-term market opportunity have improved materially, and management has committed to organic revenue growth of at least 10% annually through 2030, alongside substantial margin expansion. (sec.gov)
For tomorrow’s report, however, investors should focus less on distant CMS or G8 possibilities and more on three immediate tests:
A clean beat plus a credible guidance raise would reinforce the recovery. A consensus-level quarter with no improvement in U.S. momentum may be viewed as insufficient after the stock’s recent rebound.